Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process.

The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of a New Drug Application, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA.

Pharmaxis previously agreed on the trial design with the European regulatory agency (EMEA). This trial will therefore form the basis of a marketing application in both the U.S. and Europe.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, double-blind investigation of Bronchitol twice daily in approximately 350 adults with bronchiectasis. Participants will be treated for 52 weeks and the primary endpoints are reduction in frequency of exacerbations and improvement in quality of life. Secondary endpoints include time to first exacerbation and duration of exacerbation. Additional secondary endpoints are antibiotic use, sputum volume, exercise tolerance and lung function measurements. The trial includes health economic analysis and will be conducted in centers across Europe and the U.S.

This trial is the second Phase III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a successful shorter trial reported last year.

Pharmaxis CEO, Alan Robertson, said the company was pleased to have concluded its discussions with the FDA and the EMEA.

''We believe this phase 3 trial design will allow us to thoroughly demonstrate the clinical benefits of Bronchitol in a patient populat
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... MINNEAPOLIS , March 3, 2015  Uroplasty, ... company that develops, manufactures and markets innovative proprietary ... meeting for shareholders and analysts on Thursday, March ... at Uroplasty,s corporate headquarters in Minnetonka ... , President and Chief Executive Officer, will host ...
(Date:3/3/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announces that ... will be making a corporate presentation at the 27th ... Dana Point, CA.  Dr. Ren will present on March ...
(Date:3/2/2015)... , March 2, 2015 Cure SMA recently announced ... of Biomedical Research (CALIBR). This funding is an extension of ... with a $700,000 Cure SMA grant to Dr. Peter ... program, "Optimization of Small Molecules that Increase SMN2 ... Survival motor neuron (SMN) protein is critical to the function ...
Breaking Medicine Technology:Uroplasty to Host Investor Meeting at Corporate Headquarters 2Uroplasty to Host Investor Meeting at Corporate Headquarters 3Uroplasty to Host Investor Meeting at Corporate Headquarters 4Uroplasty to Host Investor Meeting at Corporate Headquarters 5Uroplasty to Host Investor Meeting at Corporate Headquarters 6CASI Pharmaceuticals To Present At The 27th Annual ROTH Conference 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3
... late 2008 or early 2009 -, SAN CARLOS, ... today announced that it has enrolled the first patient ... tolerability and,pharmacokinetics of bolus plus infusion dosing of NU172, ... "We were very encouraged by the findings of ...
... MOUNTAIN VIEW, California, June 4 BN,ImmunoTherapeutics, Inc. ... vaccine candidate against prostate cancer., A Phase ... patients with,non-metastatic as well as hormone-insensitive prostate cancer ... the trial include examining,the ability of the vaccine ...
Cached Medicine Technology:Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 2Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 3BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2
(Date:3/3/2015)... Angeles, CA (PRWEB) March 03, 2015 ... Boost , a fast weight loss product that is ... country. This is because it contains ingredients that help ... Boost is a new combination diet product thought to ... Metabolism Boost contains three ingredients, all directed at ...
(Date:3/3/2015)... Getting to the truth of the matter is ... at stake. So when it comes to physical therapy – ... – it’s vital to separate fact from fiction in order ... Sridhar Yalamanchili, PT, MSPT, and Director of Rehabilitation at ... nationwide survey by the American Physical Therapy Association (APTA) revealed ...
(Date:3/3/2015)... Spain (PRWEB) March 03, 2015 The authors ... best health care for the future is a good and ... by Xlibris UK) the authors have a created an ingenious ... & cooked vegetarian & vegan meals. , “Crude Food” ... food intolerances and allergies, mainly caused by over processed ...
(Date:3/3/2015)... HealthCarePoint (HCP) , the ... today that it has completed development of the ... Standards Consortium (CDISC). HCP will continue to provide ... training and certifications globally. HCP’s in-kind services will ... as well as development of dynamic identification for ...
(Date:3/3/2015)... 03, 2015 Motion Graphics ... of a new plugin FCPX3D Confetti designed exclusively for ... exploding transition using confetti particles inside FCPX,” said Christina ... FCPX3D Confetti transition, users will have fun as they ... from one clip to the next with 3D tumbling ...
Breaking Medicine News(10 mins):Health News:Diet Doc Discloses the Ingredients in their Powerful New Metabolism Boost for Controlled Appetite, Fast Weight Loss and Improved Mood 2Health News:Diet Doc Discloses the Ingredients in their Powerful New Metabolism Boost for Controlled Appetite, Fast Weight Loss and Improved Mood 3Health News:Diet Doc Discloses the Ingredients in their Powerful New Metabolism Boost for Controlled Appetite, Fast Weight Loss and Improved Mood 4Health News:Separating Fact from Fiction about Physical Therapy 2Health News:Separating Fact from Fiction about Physical Therapy 3Health News:New book ‘Crude Food’ gives readers ingenious ways to create healthy meals 2Health News:New book ‘Crude Food’ gives readers ingenious ways to create healthy meals 3Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:A new Confetti Generator entitled FCPX3D Confetti was released today from Pixel Film Studios for Final Cut Pro X 2
... News) -- Premature infants have fewer types of bacteria in ... However, the bacteria and other microbes often found ... researchers from Duke University Medical Center noted. "You see ... they seem to be stuck -- they have fewer types ...
... function were common and long-lasting during the first ... to a new study from Johns Hopkins University ... risk factor for impaired physical function. "Early ... evaluated as a potential,intervention to improve long-term outcomes ...
... , THURSDAY, Dec. 8 (HealthDay News) -- Increased consumption ... of breast cancer recurrence, new research finds. Researcher ... University of California, San Diego, looked at changes in ... potatoes, that breast cancer survivors ate over a one-year ...
... quantifying the amount of three different HER growth proteins, ... breast cancer , did not predict a patient,s outcome ... Herceptin, say Mayo Clinic researchers. HER2-positive breast cancer gets ... factor receptor 2 that promotes cancer cell growth. ...
... By Serena Gordon HealthDay Reporter , THURSDAY, Dec. ... the risk of stroke dropped about 22 percent in people ... These people didn,t yet have high blood pressure, but they ... significant reduction in the rate of heart attacks for people ...
... used to spot where people live, satellite images of ... festering among them, too, according to new research. ... Dec. 9 that nighttime-lights imagery presents a new ... revealing the population boom that typically coincides with seasonal ...
Cached Medicine News:Health News:Preemies Infected With More Dangerous Types of Bacteria: Study 2Health News:Depressive symptoms and impaired physical function are frequent and long-lasting after ALI 2Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 2Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 3Health News:Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer 2Health News:Treating Prehypertension Lowers Stroke Risk: Study 2Health News:Treating Prehypertension Lowers Stroke Risk: Study 3Health News:Princeton study: Nighttime images help track disease from the sky 2Health News:Princeton study: Nighttime images help track disease from the sky 3Health News:Princeton study: Nighttime images help track disease from the sky 4Health News:Princeton study: Nighttime images help track disease from the sky 5Health News:Princeton study: Nighttime images help track disease from the sky 6
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
... EMR,systems require you to,change the ... only,electronic patient charting,solution designed to ... around,five specific criteria to,enhance overall ... you to see,more patients in ...
... StatStrip point-of-care glucose monitor elevates bedside glucose ... performance that approaches the quality of central ... well glucose measuring strip technology. Current ... Novas exclusive Multi-Well system measures and corrects ...
... EMS provides service to companies in many ... stores and restaurants.There are no hidden charges at ... equipment and service are among the lowest in ... array of services ranging from MasterCard/Visa processing to ...
Medicine Products: